123344-02-5

Basic information

• Product Name: 2,4-DIFLUORO-5-NITROANILINE
• Synonyms: 2,4-DIFLUORO-5-NITROANILINE
• CAS NO: 123344-02-5
• Molecular Formula: C₆H₄F₂N₂O₂
• Molecular Weight: 174.1
• Product Categories: Fluorine series
• Mol File: 123344-02-5.mol
• Article Data: 11

Chemical Properties

• Melting Point: 94-96°C
• Boiling Point: 309.4°C at 760 mmHg
• Flash Point: 140.9°C
• Appearance: /
• Density: 1.554g/cm³
• Vapor Pressure: 0.00064mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 1.02±0.10(Predicted)
• CAS DataBase Reference: 2,4-DIFLUORO-5-NITROANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIFLUORO-5-NITROANILINE(123344-02-5)
• EPA Substance Registry System: 2,4-DIFLUORO-5-NITROANILINE(123344-02-5)

Safety Data

• Hazardous Substances Data: 123344-02-5(Hazardous Substances Data)

Usage

Description

2,4-Difluoro-5-nitroaniline, a chemical compound with the molecular formula C6H4F2N2O2, is a nitroaniline derivative characterized by the presence of a nitro group (NO2) and an aniline group (C6H5NH2). It is known for its versatile chemical properties, making it a valuable component in organic synthesis and pharmaceutical research.

Uses

Used in Organic Synthesis:
2,4-Difluoro-5-nitroaniline is used as a building block in organic synthesis for the production of various organic chemicals, including dyes and pharmaceuticals. Its unique structure and reactivity contribute to the development of new chemical compounds for a range of applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2,4-Difluoro-5-nitroaniline is utilized as a key intermediate in the synthesis of potential drug candidates. Its chemical properties allow for the creation of novel compounds with therapeutic potential, addressing various medical needs.
It is crucial to handle 2,4-Difluoro-5-nitroaniline with care due to its potential toxicity and harmful effects if not properly managed.

InChI:InChI=1/C6H4F2N2O2/c7-3-1-4(8)6(10(11)12)2-5(3)9/h1-2H,9H2

Upstream product

• 446-35-5 2,4-Difluoronitrobenzene 
• 367-25-9 2,4-difluorophenylamine 
• 327-92-4 1,5-difluoro-2,4-dinitrobenzene 

Downstream Products

• 1421372-67-9 N¹-(2-(dimethylamino)ethyl)-5-methoxy-N¹-methyl-N⁴-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine 
• 1421372-66-8 N?2?[[2?(dimethylamino)ethyl]methylamino]?4?methoxy?5?[[4?(1?methyl?1H?indole-3-yl)-2-pyrimidinyl]amino]aniline 
• 1421373-65-0 [N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)propen-2-amide] 
• 1075705-01-9 4-fluoro-2-methoxy-5-nitro-phenylamine 
• 675103-17-0 N⁴-cyclohexylmethyl-2-(4-methyl-piperazin-1-yl)-5-nitro-N¹-phenyl-benzene-1,4-diamine 

Relevant articles and documents

Amino pyrimidine compound and preparation method and application thereof

The invention relates to an amino pyrimidine compound and a preparation method and application thereof. The amino pyrimidine compound has a structure as shown in a formula I. The formula is shown in the description. The compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The invention further relates to a medicine composition comprising the compound, a preparation methodand application thereof in preparation of anti-tumor medicines.

Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine

We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time. Thus, the scope was to develop a new class of advanced compounds maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II. Extending this scaffold with suitable residues resulted in an interference with the kinase's R-Spine. By synthesizing 69 compounds, we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM. This new binding mode was validated by cocrystallization, showing all binding interactions typifying type I1/2 binding. Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.

SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.